Targeting the host factor HGS-viral membrane protein interaction in coronavirus infection.
Summary
A genome-wide CRISPRi screen identified HGS as essential for coronavirus assembly via direct interaction with the M protein, enabling ERGIC trafficking. HGS-targeting peptides and riboflavin tetrabutyrate disrupted this interaction, blocking virion assembly and demonstrating broad anti-coronavirus activity in vitro and in vivo.
Key Findings
- HGS directly binds coronavirus M protein to enable ERGIC trafficking and virion assembly; HGS deficiency retains M in ER and blocks assembly.
- M-derived peptides and riboflavin tetrabutyrate (RTB) bind HGS, disrupt HGS–M interaction, and prevent virion assembly.
- Agents targeting HGS demonstrated broad anti-pan-coronavirus activity in vitro and in vivo.
Clinical Implications
Although preclinical, targeting HGS could yield broad-spectrum therapeutics less prone to resistance than viral protein inhibitors. Riboflavin tetrabutyrate merits pharmacokinetic/toxicity profiling and early-phase trials for coronavirus diseases.
Why It Matters
This work reveals a conserved, druggable host-virus interface and provides a repurposed compound with in vivo efficacy, opening a host-directed antiviral modality with pandemic relevance.
Limitations
- Preclinical study; human safety, pharmacokinetics, and optimal dosing are unknown
- Host-target engagement may entail on-target toxicity; off-target effects of RTB need evaluation
Future Directions
Advance RTB and peptide inhibitors into ADME/toxicology studies, assess efficacy in relevant animal disease models, and explore combination with direct-acting antivirals to mitigate resistance.
Study Information
- Study Type
- Basic/Mechanistic Research
- Research Domain
- Pathophysiology/Treatment
- Evidence Level
- V - Preclinical mechanistic study with in vitro and in vivo validation
- Study Design
- OTHER